Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.36 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11947609 | 1.00 | L3MBTL1 (0.40) | L3MBTL1KDM4EGRM1DGAT1PRNP | |
| SCHEMBL4346798 | 1.00 | L3MBTL1 (0.40) | L3MBTL1KDM4EGRM1DGAT1PRNP | |
| SCHEMBL14390044 | 0.94 | GRM1 (0.40) | L3MBTL1KDM4EGRM1DGAT1PRNP | |
| SCHEMBL11947610 | 0.86 | ALDH1A1 (0.43) | L3MBTL1KDM4EGRM1DGAT1PRNP | |
| SCHEMBL14390047 | 0.85 | DGAT1 (0.38) | L3MBTL1KDM4EGRM1DGAT1PRNP | |
| SCHEMBL4188323 | 0.83 | BACE1 (0.39) | MEN1KMT2ALTC4SBACE1ALDH1A1 | |
| SCHEMBL4509933 | 0.80 | CRHR1 (0.45) | MEN1KMT2ACRHR1MAPK1NPSR1 | |
| SCHEMBL4230077 | 0.78 | USP14 (0.37) | KDM4EDGAT1CRHR1OPRK1S1PR1 | |
| SCHEMBL4222418 | 0.78 | USP14 (0.37) | KDM4EDGAT1CRHR1OPRK1S1PR1 | |
| SCHEMBL4360534 | 0.76 | CETP (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410275-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8232403-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| EP-2024356-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | Novartis AG (CH) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007128568-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | CETP, LCAT, CES1 | L3MBTL1 3957/4885KDM4E 1621/4885GRM1 4861/4885 |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | CETP, LCAT, CES1 | L3MBTL1 3957/4885KDM4E 1621/4885GRM1 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.